Company: MYGN
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0000899923-25-000086
Chunk: 93

Company: MYRIAD GENETICS INC
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 93
---
The results of operations for the six months ended June 30, 2025 and 2024 are discussed below.  

Revenue

The following table summarizes revenue changes in our core product categories:

Six months ended June 30,% of Total Revenue(in millions)20252024Change20252024Hereditary Cancer$182.6 $179.6 $3.0 44%44%Tumor Profiling60.7 63.5 (2.8)15%15%Prenatal96.9 88.7 8.2 24%21%Pharmacogenomics68.8 81.9 (13.1)17%20%Total revenue$409.0 $413.7 $(4.7)100%100%

The following table summarizes volume changes in our core product categories:

Six months ended June 30,(in thousands)20252024% ChangeVolume:Hereditary Cancer151 144 5%Tumor Profiling24 28 (14)%Prenatal332 345 (4)%Pharmacogenomics262 253 4%Total769 770 —%

25

Revenue decreased $4.7 million for the six months ended June 30, 2025 compared to the same period in the prior year. For the six months ended June 30, 2024, we recognized $9.3 million of revenue for tests in which the performance obligation was met in a prior period, including $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. For the six months ended June 30, 2025, revenue for tests in which the performance obligation was met in a prior period was immaterial. 

Pharmacogenomics revenue decreased $13.1 million for the six months ended June 30, 2025 compared to the same period in the prior year due primarily to a 19% decrease in the average revenue per test. Pharmacogenomics revenue for the six months ended June 30, 2025 has been negatively impacted by UnitedHealthcare’s change in coverage of the GeneSight test under its commercial, individual exchange benefit, and certain managed Medicaid plans. We expect this coverage decision will continue to negatively affect revenue in future periods. Tumor Profiling revenue decreased $2.8 million for the six months ended June 30, 2025 compared to the same period in the prior year due primarily to